Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PB
Invesco Biotechnology & Genome ETF
PBE
Volume
11.13K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PB
PBE
PB
Invesco Biotechnology & Genome ETF
PBE
News
·
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
AUM
N/A
Volume
11.13K
Yield
0.08%
Chart
Earnings
News
About
Dividends
Insider
Filings
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.
Zacks Investment Research · Oct 14, 2026
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.
Zacks Investment Research · Oct 13, 2026
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.
The Motley Fool · Jul 30, 2026
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks Investment Research · May 13, 2024
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks Investment Research · May 10, 2024
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks Investment Research · Mar 13, 2024
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks Investment Research · Mar 5, 2024
Where Are Biotech ETFs Headed After Q4 Earnings?
Look into how Biotech ETFs performed after Q4 earnings.
Zacks Investment Research · Feb 14, 2024
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks Investment Research · Jan 9, 2024
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks Investment Research · Jan 3, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PB
PBE
Invesco Biotechnology & Genome ETF
Buy
Sell
Market
Limit
Soon
PBE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PBE yet.
Related Tickers
Earnings
Dividends
Last · Sep 21
Quarterly
Amount
$0.0190
Yield
1.39%
Annual
$1.33